Jun 26, 2026 08:02AM
Jun 26, 2026 08:00AM
May 15, 2026 04:15PM
May 12, 2026 08:09AM
May 12, 2026 08:00AM
May 8, 2026 08:00AM
Apr 16, 2026 08:04AM Ensysce receives approval for final phase of opioid overdose study
Apr 16, 2026 08:00AM
Apr 9, 2026 06:13AM
Apr 7, 2026 08:17AM
Apr 7, 2026 08:00AM
Mar 31, 2026 06:51AM
Mar 30, 2026 04:50PM
Mar 4, 2026 08:45AM Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
Mar 3, 2026 08:02AM
Mar 3, 2026 08:00AM
Feb 25, 2026 08:00AM
Feb 23, 2026 08:00AM
Jan 28, 2026 08:02AM
Jan 28, 2026 08:00AM
Jan 21, 2026 08:03AM Ensysce Biosciences receives Brazil patent for opioid technologies
Jan 21, 2026 08:00AM
Jan 8, 2026 08:00AM
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 9, 2025 08:00AM
Dec 9, 2025 08:00AM
Dec 2, 2025 08:05AM Ensysce receives patent allowance for MPAR overdose protection technology
Dec 2, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 17, 2025 08:06AM
Nov 17, 2025 08:05AM
Nov 16, 2025 11:46PM
Nov 14, 2025 04:15PM Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Sep 4, 2025 08:00AM
Aug 19, 2025 08:00AM
Aug 13, 2025 06:15PM
Aug 13, 2025 04:15PM
Jul 31, 2025 08:00AM
Jul 31, 2025 08:00AM
Jul 16, 2025 08:00AM Ensysce Biosciences begins phase 3 trial for abuse-resistant opioid PF614
Jul 16, 2025 08:00AM
Jun 24, 2025 08:00AM
Jun 11, 2025 08:00AM
Jun 4, 2025 08:12AM
Jun 4, 2025 08:00AM
May 14, 2025 04:58PM
May 13, 2025 04:15PM Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 12, 2025 08:00AM

409,038 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All